Allergan Patent For Zymar Not Valid: Apotex

Law360, New York (February 23, 2009, 12:00 AM EST) -- In a patent dispute over Allergan Inc.'s antibiotic Zymar, which is used to treat bacterial infections in the eye, Apotex Inc. is arguing that its proposed generic version would not infringe because the patent for Zymar is void for inequitable conduct.

In an answer and counterclaims filed Friday in the U.S. District Court for the District of Delaware, Apotex alleges that Allergan and the two Japanese companies that hold the patent-at-issue, Senju Pharmaceutical Co. Ltd. and Kyorin Pharmaceutical Co. Ltd., failed to disclose important information about...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.